PTHLH and prostate carcinoma: A striking example of this comes from Deftos et al. (104) where mice injected with dormant prostate cancer cells expressing the full-length PTHrP (1–173) molecule developed more extensive bone lesions than those injected with PTHrP (1–87) which lacks the full NLS, osteostatin region, and critical mitogen regulatory sequences contained in the carboxy terminus.